anti-Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8) Antikörper

Human Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8) Interaktionspartner

1. Hodgkin and Reed/Sternberg (HRS) cells shared typical transcriptome patterns with CD30+ B cells, suggesting that they originate from these lymphocytes or acquire their characteristic features during lymphomagenesis. By comparing HRS to normal CD30+ B cells we redefined aberrant and disease-specific features of HRS cells.

2. Review of 585 cases found strong and uniform positive CD30 staining in Hodgkin lymphoma, anaplastic large cell lymphoma, and embryonal carcinoma as well as variable CD30 staining in non-Hodgkin lymphomas. In addition, CD30 staining was found in some cases of neuroblastoma (particularly in cells with ganglion differentiation), myeloid neoplasms, neoplasm with chondrocytic differentiation, and hemangiomas.

3. CD30 and CD30L were involved in pulmonary vascular remodeling and inflammatory response in COPD.

4. CD30+ diffuse large B-cell lymphoma has characteristic clinicopathological features mutually exclusive with MYC gene rearrangement and negatively associated with BCL2 protein expression.

5. Data suggest that CD4+ T cell-associated HIV-1 RNA is often highly enriched in cells expressing CD30; cells expressing this marker considerably contribute to total pool of transcriptionally active CD4+ lymphocytes in individuals on suppressive anti-retroviral drug therapy; CD30 may be a marker of residual, transcriptionally active HIV-1 infected cells in blood and in gut-associated lymphoid tissue.

6. The stable elevation in classical Hodgkin lymphoma risk with elevated levels of sCD30 and IL6 across 4 or more years prior to diagnosis may also reflect a B-cell-stimulatory environment that promotes the genesis of these cancers.

7. extranodal NK/T-cell lymphoma, nasal type(ENKTL) is the most common type of mature T-cell and NK-cell lymphoma diagnosed at our institution. CD30 is frequently expressed in ENKTL and represents a therapeutic target; however, it may not be a prognostic marker.

8. This study suggests that in patients with CD30+ lymphoproliferative disorders, an aggressive clinical course cannot be defined by the presence of TP63 rearrangements, as was recently shown in systemic ALK negative anaplastic large cell lymphoma.

9. Data suggest that Brentuximab Vedotin (SGN-35) damaged CD30 ligand (CD30L)-immune cells through CD30 extracellular vesicles (EVs).

10. median FoxP3+ Treg count was higher in CD30+ than in CD30- posttransplant lymphoproliferative disorders, 3.0 vs 0

11. Variant histology is common in pediatric NLPHL, especially types C and E, which are associated with IgD expression. Type C variant histology and possibly type D are associated with decreased EFS, but neither IgD nor CD30 are adverse features. Variant histology may warrant increased surveillance, but did not affect overall survival.

12. Expression of CD30 in patients with both DLBCL and other aggressive B-cell lymphomas and the absence of MYC oncogene-driven proliferation in the majority of these tumors suggests that brentuximab may be a particularly effective form of targeted therapy in the subset of patients with high CD30 expression.

13. Prevalence of the CD30 (Ki-1) antigen in human solid tumors was summarized.

14. Higher serum sCD30 levels were associated with an increased risk of bacterial infection after kidney transplantation.

15. CD30 expression was detected in up to 25% of cases of diffuse large B-cell lymphoma and was more frequent in tumors without MYC rearrangement. CD30 expression was not associated with overall survival in R-EPOCH-treated de novo DLBCL patients.

16. CD30 facilitates phosphorylation of heat shock factor 1, activates heat shock promoter element, and induces heat shock protein (HSP) 90.

17. this study shows that polyclonal and allogeneic stimulation induced higher levels of CD30 transcripts in end-stage renal disease patients compared to control patients

18. CD30 expression was not associated with prognosis in our cohort of de novoDLBCL, including in patients who received aggressive chemotherapy. CD30 expression and MYC rearrangement were mutually exclusive in de novoDLBCL.

19. Case Report: CD30 positive lymphomatoid papulosis arising in association with cutaneous amyloidosis in a patient with multiple myeloma.

20. The heterogeneity of CD30 expression in refractory or relapsed peripheral T-cell lymphoma patients indicates the likelihood for better response for patients with strong CD30 expression by tumor cells.

Mouse (Murine) Tumor Necrosis Factor Receptor Superfamily, Member 8 (TNFRSF8) Interaktionspartner

1. This study demonstrated the amelioration of MOG35-55 peptide-induced active EAE in CD30 KO mice. CD30 was expressed limitedly on CD4 T cells at the induction phase of experimental autoimmune encephalomyelitis.

2. Data indicate that CD30L/CD30 axis plays a modulatory role in the pathogenesis of experimental autoimmune encephalomyelitis (EAE).

3. role in the maintenance and activation of IL-17A-producing gammadelta T cells

4. These results suggest that CD30 signaling plays an important role in the activation of IL-17A-producing Vgamma1(-) Vgamma4(-) gammadelta T cells bearing Vgamma6 at an early stage of BCG infection.

5. Interference of the CD30-CD30L pathway reduces atherosclerosis development.

6. CD30L/CD30 pathway acts as an accelerator of enteritis in a murine disease model

7. role of CD30L/CD30 interactions in allergic rhinitis; results suggest that CD30L plays an important role in allergic rhinitis

8. Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice.

9. Studies demonstrate that CD30L/CD30 signaling executed by the T-T cell interaction plays a critical role in Th17 cell differentiation.

10. CD30 can signal in a completely TCR-independent fashion to induce IL-13 production by effector T cells.

11. Immunity to CD30 could play a role in Marek disease lymphoma regression.

12. Deficiencies in OX40 and CD30 signals were additive, secondary Ab responses were ablated.OX40/CD30 double-knockout OTII transgenic T cells fail to survive compared with normal T cells when cocultured with CD4(+)CD3(-) cells in vitro.

13. CD30 plays an important role in the generation of long-lived memory CD8+ T cells, at least partly by triggering homing receptors for T(central memory) cells.

14. early CD30 signaling is critical for regulatory T cells-mediated acute graft-versus-host disease protection after major MHC-mismatch bone marrow transplantation

15. These results indicate that CD30 is a regulator of T(h)2 responses in the effector-memory phase and a regulator of IL-13 production in memory cells in the lung.

16. CD30L/CD30 signaling is involved in development of both OXA- and TNBS-induced colitis. Modulation of CD30L/CD30 signaling by mAb could be a novel biologic therapy for inflammatory bowel diseases.

17. CD30 and OX40 signals are both required for the survival but not commitment of CD4 T helper type 1 (Th1) cells.

18. Signaling executed by CD30positive T cell interaction with CD30Lpositive T cells plays a critical role in amplification of T helper type (Th)1 responses that able to produce interferon-gamma against Mycobacterium bovis bacillus Calmette-Guerin infection.

19. ko mice exhibite delayed structuring of pulmonary granulomas and reduced recruitment of lymphocytes after infection with erogenic Mycobacterium avium

20. CD30 signals from lymphoid tissue inducer cells were a primitive mechanism to recruit and prime CD4 T cells